Picture Kentro Design Is Key to Your Success Berlin 650x100px

Person › Details

Stéphane Boissel (SparingVision S.A.S.)

Boissel, Stéphane (SparingVision 202010– CEO before Sangamo + TxCell + Genclis + Transgene + Innate Pharma + Lazard)

	Organisation	SparingVision S.A.S.
	Former/major organisation	TxCell S.A. (Euronext Paris: TXCL)
	Product	SPVN06 mutation-agnostic AAV gene therapy for ofretinitis pigmentosa (SparingVision)
	Product 2	gene therapy

Record changed: 2022-09-16

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

More documents for Stéphane Boissel

[1] SparingVision S.A.S.. (9/14/22). "Press Release: SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases"....
[2] Intellia Therapeutics, Inc.. (10/13/21). "Press Release: Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology". Cambridge, MA & Paris....
[3] SparingVision S.A.S.. (10/21/20). "Press Release: SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer". Paris....
[4] Sangamo Therapeutics, Inc.. (7/23/18). "Press Release: Sangamo Therapeutics to Acquire TxCell". Richmond, CA & Valbonne....
[5] TxCell S.A.. (7/9/18). "Press Release: TxCell Exercises In-license Option to the University of British Columbia's Intellectual Property Rights of the HLA-A2 CAR-Treg Program". Valbonne....
[6] TxCell S.A.. (5/31/18). "Press Release: TxCell Names Lonza as Its CAR-Treg Cellular Product Manufacturer". Valbonne & Basel....
[7] TxCell S.A.. (10/25/17). "Press Release: TxCell Renegotiates OCABSA Financing Option to Extend Cash Runway [Not for distribution in the United States of America, Canada, Australia and Japan]". Valbonne....
[8] TxCell S.A.. (6/19/17). "Press Release: TxCell Appoints Lentigen Technology, Inc. to Manufacture the Lentiviral Vector for Its First CAR-Treg Program in Transplant Rejection". Valbonne....
[9] TxCell S.A.. (3/9/17). "Press Release: TxCell 2016 Financial Results". Valbonne....
[10] TxCell S.A.. (2/22/17). "Press Release: TxCell Successfully Completes a €11 Million Capital Increase [Not for release directly or indirectly in the United States of America, Canada, Australia or Japan]". Valbonne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]